3 completed, 1 active not recruiting, 1 terminated. 4 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow PTC596: new trials by email Literature Review of PTC596 trials Research Report on PTC596
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) Unesbulin, Dacarbazine, Placebo - Leiomyosarcoma | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 359 | 2022-05-23 | 2025-06-13 |
| A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Unesbulin, Dacarbazine - Leiomyosarcoma | Phase 1 | Completed | PTC Therapeutics | 41 | 2019-03-13 | 2024-03-15 |
| A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma PTC596, Radiotherapy - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1 | Active not recruiting | Nationwide Children's Hospital | 64 | 2018-08-01 | 2026-03-27 |
| Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy Unesbulin - Ovarian Cancer | Phase 1 | Completed | University of Oklahoma | 27 | 2017-08-28 | 2024-04-23 |
| PTC596 in Patients With Advanced Solid Tumors PTC596 - Cancer | Phase 1 | Completed | PTC Therapeutics | 31 | 2016-01-01 | 2017-12-08 |
Leiomyosarcoma (2) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Neoplasms (1) · Ovarian Neoplasms (1)
PTC Therapeutics (3) · Nationwide Children's Hospital (1) · University of Oklahoma (1)
United States (5) · Canada (2) · Australia (1) · Brazil (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
Edward O'Mara, MD (1) · Kathleen Moore, MD (1) · Margot Lazow, MD (1) · Mark Rance, MD (1) · Maryam Fouladi, MD (1)